NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • AI in Drug Discovery and Biomedicine
    31 March 2025
    Barcelona

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download

  • Life Sciences Conference – Van Lanschot Kempen
    2 - 3 April 2025
    Amsterdam

    download

  • Swisss Biotech Day
    5 - 6 May 2025
    Basel

    download
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)<
29 Mar 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update<
28 Mar 2025

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Johnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights<
25 Mar 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cash Position Expected to Support Operations into 2H 2026
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET<
25 Mar 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress<
24 Mar 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock<
18 Mar 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Aggregate gross proceeds to Mineralys from the offering were approximately $201.2M
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease<
13 Mar 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology<
11 Mar 2025

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock<
11 Mar 2025

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Underwritten public offering of $250.0 million of shares of its common stock
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension<
10 Mar 2025

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trial

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.